ehealth radio network
Dr. Stephen Harrison Discusses Clinical Importance of FibroScan Technology

Dr. Stephen Harrison Discusses Clinical Importance of FibroScan Technology

May 8, 2021

 

sHarrison_May21.png

 

Dr. Stephen A. Harrison, gastroenterologist and hepatologist, joins eHealth Radio and the Health News & Technology Channels to discuss the role FibroScan technology has played in the management of patients with liver disease.


Listen to interview with host Eric Michaels and guest Dr. Stephen A. Harrison discuss the following:

  1. Please share with us the ongoing need for assessing liver stiffness and fat as part of a liver health assessment – and why the detection of fatty liver disease remains such a pressing challenge for Americans, especially during the COVID-19 pandemic.

  2. How does FibroScan tie into your clinical workflow? How might other clinicians be able to utilize it?

  3. Tell us about the successes you are seeing as a result of the FibroScan FAST score implementation and the research you’ve gathered from it.
  4. What work is being done to improve any previous high screen failure rates? Has there been any improvement since late phase clinical trials?

  5. Do you have any patient stories that you could share with us about the success of monitoring liver stiffness and fat with FibroScan?

  6. What will your focus be on continuing to bring awareness of NAFLD diagnosis and treatment in a post-pandemic world?

  7. Where do you see this research going in terms of the management of liver disease and improving outcomes for patients?

Dr. Stephen A. Harrison, M.D., FACP, FAASLD, retired COL, USA, MC, gastroenterologist and hepatologist, medical director of Pinnacle Clinical Research, and visiting professor of Hepatology, University of Oxford.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

logo_echosens_gradient6xp78.png

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV

Bastille Delivers Zone Detection for Healthcare Sector

Bastille Delivers Zone Detection for Healthcare Sector

May 5, 2021

 

Bob_Baxley_20218895b.png

 

Bob Baxley, CTO at Bastille Networks a company that delivers enterprise threat detection through software-defined radio joins eHealth Radio and the Technology Channel.


Listen to interview with host Eric Michaels and guest Bob Baxley discuss the following:

  1. Can you provide our listeners a background on Bastille and why the company was created?
  2. What are some of the pain points in radio frequency that Bastille is addressing?
  3. How will radio frequency’s complexity in the workplace change as workers return based on the devices they bring and the devices that they may be asked to wear?
  4. What are the benefits of using Bastille's technology for zone detection to mitigate the unforeseen new threats from other contact tracing technologies?
  5. What are some steps that the healthcare industry can improve to protect facilities and patient data from adversaries?

For more than a decade, Dr. Bob Baxley has been a technology leader in implementing machine learning algorithms for software defined and cognitive radios. At Bastille, Bob serves as Chief Technology Officer where he leads the development of systems to sift through massive amounts of radio frequency data to protect enterprises from radio threats.

Prior to joining Bastille, Bob was the Director of the Software Defined Radio Lab at Georgia Tech, where he led basic and applied research projects for organizations including NSF, ONR, Army, DoD, Air Force and DARPA. He has published more than 100 peer-reviewed papers and patents, is the receipt of various research awards, and is a Senior Member of the IEEE. He also led the GTRI team that competed in the DARPA Spectrum Challenge and placed second out of 90 teams.

 

Bastille_Logo68yg6.png

 

Website: www.bastille.net

Social Media Links:
Twitter: twitter.com/bastillenet 
Linkedin: linkedin.com/company/bastille-networks

How the pandemic has accelerated innovation in healthcare: A conversation with Karly Rowe from Experian Health

How the pandemic has accelerated innovation in healthcare: A conversation with Karly Rowe from Experian Health

April 8, 2021

 

Karley_Rowe8x5o2.jpeg

 

Karly Rowe, Vice President of Patient Access, Identity & Care Management Product for Experian Health that works with more than 3,200 hospitals and 10,000 other healthcare organizations representing 500,000 plus providers to provide data-driven solutions that support revenue cycle management, identity management, patient engagement and care management joins eHealth Radio and the Health Care and Health News Channels.


Listen to interview with host Eric Michaels and guest Karly Rowe discuss the following:

  1. Can you tell us about Experian Health and your role within the company?
  2. Any discussion of healthcare today is framed by the COVID-19 pandemic. From your business, your line of sight, what has the pandemic put in the spotlight?
  3. In the early days of the pandemic, some of our healthcare organizations estimated 1,800 duplicate records were being created every 24 hours, so it is a fair bet that the numbers are even greater now as people flock to schedule vaccines. How does the growing volume of patient traffic challenge our healthcare systems?
  4. How would a shift to standardized medical records, possibly even a universal patient ID number, help healthcare systems and health outcomes?
  5. What direction is the industry headed and what pain points are you solving for as you look to the future?

Summary: While approximately 25% of patients used patient portals prior to COVID-19, more than 235 million adults will likely interact with a patient portal or telehealth service for the first time. This new interaction sparks opportunity – an opportunity for patients to think differently about the role they are taking/playing in managing their health and an opportunity for healthcare organizations to think about how to build on and advance this newly formed relationship.


Karly Rowe is responsible for the Patient Access, Identity, and Care Management product portfolios at Experian Health. Leveraging her diverse background across credit, retail, and healthcare, Karly is responsible for finding new ways to leverage Experian’s data and analytical capabilities to develop new, innovative solutions for the healthcare industry.

Karly holds a Masters of Business Administration from Arizona State University and a Bachelor’s degree in Marketing Management and Retail Management from Syracuse University. She resides in Scottsdale, Arizona with her husband and two sons.

 

Experian_Health_Stacked_RGBbp6av.jpg

 

Website: experian.com/healthcare

Social Media Links:
Twitter: twitter.com/Experian_Health
Linkedin: linkedin.com/company/experian

COVID-19 most frequently asked questions for returning to work

COVID-19 most frequently asked questions for returning to work

April 3, 2021

 

Dr_Nitin_Desaibh9m8.png

 

Dr. Nitin Desai, an Internal Medicine Physician practicing in North Carolina for over 24 years and the Chief Medical Officer of COVID PreCheck, a digital health passport related to COVID-19 joins eHealth Radio and the Health News Channel.


Listen to interview with host Eric Michaels and guest Dr. Nitin Desai discuss the following:

  1. Now that multiple vaccines are available, should employers go back to business as usual?
  2. As employees return to work what should they expect from their employers to safeguard their health and safety?
  3. What would you recommend business leaders do to support a safe return to work?
  4. You have advocated using the Swiss cheese model to create safe workplaces - can you explain how it works? How does it keep employees safe?
  5. How do you see technology playing a role in return-to-work?
  6. What do you want to leave our audience (employees and employers) with?

About Dr. Nitin Desai

  • Physician entrepreneur.
  • Cofounder of Health Wizz, a Digital Healthcare venture https://www.healthwizz.com/  focused on EMR interoperability and Employee wellness.
  • Launched https://www.covidprecheck.net to assist in reopening the USA during the 2020 COVID Pandemic.
  • COVID PreCheck creates safe spaces with a software solution for employees and the workplace.
  • Experienced Physician, Medical Staff leader, and Digital health entrepreneur

COVIDPrejpg8eora.jpg

Website: https://covidprecheck.net

Social Media Links:
Facebook: facebook.com/COVIDPreCheckApp
Linkedin: linkedin.com/company/covidprecheck
Twitter: twitter.com/CPrecheck

AntiLand-Establishing Better Happiness Socially

AntiLand-Establishing Better Happiness Socially

January 23, 2021

 

txjxL0_g_400x400.jpg

 

Dr. Adi Zief-Balteriski, PHD Behavioral Science Expert and advisory to AntiLand, a truly anonymous and secure group chats messenger app that helps you mask your secret identity, make friends online and meet new people joins eHealth Radio and the Mental Health Channel.


Listen to interview with host Eric Michaels & guest Dr. Adi Zief-Balteriski discuss the following:

  1. As an expert in behavioral health, what are some of the challenges people face using social media?
  2. How is AntiLand an alternative to other known platforms? How is it better?
  3. What are the benefits of being anonymous in the AntiLand community?
  4. What type of topics are trending and how can one be part of the dialogue?
  5. What three tips do you have for those wanting to establish a better well-being or a social tune-up in 2021?

Dr. Adi Zief-Balteriski, Ph.D., Behavioral Science Expert and Product Leader, Dr. Adi Zief-Balteriski is a psychologist and product expert. She applies her expertise as a behavioral science specialist in the field of community, wellness, technology and consumer behavior. She is also a researcher in the field of well-being, human computing interaction and technology and presents her work at universities and organizations in the Bay Area.

Previously, Adi opened a successful private practice and a consulting business and engaged in product consulting for consumer and well-being products. After working several years as a consultant for startup founders in the Bay Area, she shifted her focus towards the tech world. Adi began working on products at startups focused on the well-being of individuals and communities. Later, she worked as a product manager being part of the entire product lifecycle from ideation to launch.

Adi holds a Ph.D. in clinical psychology from Palo Alto University, L.L.B in Law and B.A in Business and IT from the Interdisciplinary Center. She is also the mother of two young children and passionate about making a positive impact on people’s well-being and advocating for the empowerment of women to succeed in modern society. She is an advisor to AntiLand.

 

AntiLand_LOGO.png

Website: www.antiland.com

BioSig Technologies increases efforts in Electrophysiology and Atrial Fibrillation

BioSig Technologies increases efforts in Electrophysiology and Atrial Fibrillation

January 6, 2021

 

Ken_Londonera8jau.png

 

Ken Londoner, the Chief Executive Officer, Founder and Director of BioSig Technologies that is working to develop and deliver the advanced signal processing solutions that will unlock the future of bio-electronic medicine, starting with the PURE EP™ System joins eHealth Radio and the Heart Health and Technology Channels.


Listen to interview with host Eric Michaels and guest Ken Londoner discuss the following:

  1. Tell us a little bit about BioSig, the company’s mission and its efforts with in the medtech industry.
  2. What does PURE EP help treat?
  3. What types of current technologies are being used to treat AFib and how does your technology differ?
  4. How is BioSig’s PURE EP reshaping the future of electrophysiology? How will this technology be used in hospitals, electrophysiology labs, and other institutions?
  5. Tell us a little about BioSig’s subsidiary, ViralClear, and its potential antiviral candidate to treat COVID-19 patients.

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

 

BioSig_Tech_logo8zc44.png

 

Website: www.biosig.com

Social Media Links:
Facebook: facebook.com/biosigtechnologies
Linkedin: linkedin.com/company/biosig-technologies-inc-
Twitter: twitter.com/BioSig_Tech

The importance of accurate and precise blood volume measurement in heart failure and critical care patients

The importance of accurate and precise blood volume measurement in heart failure and critical care patients

December 23, 2020

 

DXR_Michael_headshot80zvv.png

Michael Feldschuh, the CEO of Daxor, an innovative medical instrumentation and biotechnology company focused on blood volume measurement joins eHealth Radio and the Health News and Technology Channels.


Listen to interview with host Eric Michaels and guest Michael Feldschuh discuss the following:

  1. Can you tell me a bit about yourself and how you got interested in the medical technology field that led to your involvement with Daxor?
  2. Let’s talk about BVA-100 and its benefits to physicians? How does BVA-100 differentiate from other similar technologies?
  3. How does BVA-100 allow clinicians to provide better outcomes for their patients?
  4. Are there any recent studies that validate BVA?
  5. Please give us an overview of BVA-100 and how it improves outcomes for heart failure patients?

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.

 

Daxor_Logo_Update_RGB-red_1_88w98.png

 

Website: www.daxor.com

Social Media Links:
Facebook: facebook.com/Daxorcorp 
Linkedin: linkedin.com/company/daxorcorporation 
Twitter: twitter.com/DaxorBVA

What is DehydraTECH and how is it revolutionizing drug delivery for many industries

What is DehydraTECH and how is it revolutionizing drug delivery for many industries

December 19, 2020

 

Chris_Bunka_9sn2o.png

 

Chris Bunka, the CEO of Lexaria Bioscience, a Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing joins eHealth Radio and the Health News and Pharmaceutical Channels.


Listen to interview with host Eric Michaels and guest Chris Bunka discuss the following:

  1. Please tell us a little bit about yourself, how Lexaria Bioscience started and the development of the company’s technology?
  2. What exactly are DehydraTECH and its benefits?
  3. Can you talk about your recent announcement with British American Tobacco?
  4. What are fat-soluble active molecules and how can your technology lower overall dosing with pharmaceutical ingredients?
  5. What type of drugs and areas can DehydraTECH increase bio-absorption?

Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.

DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.

Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

 

Lexaria_Bioscience_Logo_Dark_PRINT.png

 

Website: lexariabioscience.com

Social Media Links:
Facebook: facebook.com/lexariabioscience
Linkedin: linkedin.com/company/lexaria-bioscience
Twitter: twitter.com/LexariaBioCorp

The Future of Medical Recalls

The Future of Medical Recalls

December 18, 2020

 

Joan_Melendez_Post72quy.png

 

Joan Melendez, the Founder and President at health-tech startup Xcelrate UDI joins eHealth Radio and the Health News and Technology Channels. Their technology, a medical device barcode scanning solution, identifies and prevents the use of recalled and faulty medical products and devices to improve patient safety at the point of care.


Listen to interview with host Eric Michaels and guest Joan Melendez discuss the following:

  1. What is a Unique Device Identifier, and why has it become so relevant in recent times?
  2. What kind of impact are medical recalls currently having on the healthcare industry and patients?
  3. How could full-scale adoption of your barcode scanning technology change healthcare - for patients and the industry as a whole?
  4. How can technology be better used across healthcare -- for communication, organisation, data storage?
  5. The Closed Loop Automation Solution you’ve partnered on has introduced an electronic patient implant card. How will this benefit patients?

Tip: If you’ve had a medical device implanted or are about to, ask your doctor about how they are ensuring your implants are safe for use and how you will be notified of quality issues should your implants be recalled after they are implanted.


Founder and President Joan Melendez leads the team at Xcelrate UDI. Having been in the healthcare industry since her teens, Joan has become a passionate advocate for the safety of patients and for innovation in healthcare.

Xcelrate UDI is a healthcare technology and consulting services company that leverages the power of UDI (unique device identifier) barcode scanning technology to bridge the information gaps between data sources (provided by manufacturers and the FDA) for medical devices and physical supplies. Their vision? To be the industry’s most trusted partner in advancing UDI adoption to improve compliance with medical devices and reduce patient risk at the point of care.

 

UDI_Black_Logo_Transparent_background88k8c.png

 

Website: www.xcelrateudi.com

Social Media Links:
Facebook: facebook.com/xcelrateudi 
Linkedin: linkedin.com/company/xcelrate-udi 
Instagram: instagram.com/xcelrateudi

Genprex, reprogramming the course of cancer and diabetes

Genprex, reprogramming the course of cancer and diabetes

December 8, 2020

 

rodney_varner_headshot.jpg

 

Rodney Varner, the CEO of Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes joins eHealth Radio and the Cancer Information Diabetes and Health News Channels.


Listen to interview with host Eric Michaels and guest Rodney Varner discuss the following:

  1. What inspires you at Genprex?
  2. Please give us an overview of Genprex’s gene therapies in development. What is it intended to treat, and how does it work?
  3. Could you talk more specifically about Genprex’s lead product candidate GPX-001?
  4. Could you please give us some insight about GPX-002, gene therapy for people with diabetes and what is it comprised of?
  5. What are the benefits of Genprex’s targeted therapies for people with non-small cell lung cancer?

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

 

Genprex_LOGObu36u.png

 

Website: genprex.com

Social Media Links:
Facebook: facebook.com/genprexinc 
Linkedin: linkedin.com/company/genprex 
Twitter: twitter.com/genprex

Podbean App

Play this podcast on Podbean App